Hepatocellular carcinoma after direct-acting antiviral drug treatment in patients with hepatitis C virus.

Tomomi KogisoTakaomi SagawaKazuhisa KodamaMakiko TaniaiSatoshi KatagiriHiroto EgawaMasakazu YamamotoKatsutoshi Tokushige

Published in: JGH open : an open access journal of gastroenterology and hepatology (2018)

DAA did not increase the rate of HCC, even in immunosuppressed patients. However, careful follow-up for HCC recurrence is required in previously treated cases.

Keyphrases

hepatitis c virus
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
human immunodeficiency virus
prognostic factors
peritoneal dialysis
patient reported outcomes
replacement therapy
adverse drug